DGIdb - IBUPROFEN Drug Record

IBUPROFEN chembl:CHEMBL521 Approved

Alternate Names:

U-18573
NOVAPRIN
FEMAFEN
IBUMETIN
PHENSIC
NUROFEN SOLB
PACIFENE
FEVERFEN
PROFEN
IBUSPRAY
PEDEA
PROFLEX
TAB-PROFEN
MEDIPREN
CHILDREN'S ADVIL-FLAVORED
APSIFEN-F
NUROFEN RECOVERY
PAXOFEN
RELCOFEN
FENBID FTE
IBUDERM
IB-100
ORBIFEN
NUROFEN 400
CHILDREN'S ADVIL
ANADIN LIQUIFAST
FENPAED
INOVEN
LOBUFEN
NUROFEN BACK PAIN SR
EBUFAC
ANADIN ULTRA
ADVIL MIGRAINE LIQUI-GELS
IBU-TAB 200
CAP-PROFEN
PEDIATRIC ADVIL
IBULEVE
DEEP RELIEF
ANADIN JOINT PAIN
JUNIOR STRENGTH IBUPROFEN
PHORPAIN MAX STRGH
MIDOL LIQUID GELS
CHILDREN'S IBUPROFEN
JUNIOR STRENGTH ADVIL
IBUCALM
ADVIL LIQUI-GELS
FENBID
NUROFEN SINUS
RIMAFEN
FLEXIMEX
IBUMED
IBUGEL
SUSPREN
PHORPAIN
MOTRIN
NSC-256857
IBUTIME
PROFLEX SR
IBUFAC
NUROFEN PLUS
CUPROFEN PLUS
ARTHROFEN 400
IBUGEL FTE
LIDIFEN-F
ADVIL
JUNIOR STRENGTH MOTRIN
IBUPRIN
ANADIN PERIOD PAIN RELIEF
CALDOLOR
INABRIN
MIGRAFEN
IBU-TAB
IP-82
APSIFEN
CHILDREN'S MOTRIN
LIDIFEN
MOTRIN IB
M01AE01
MAXA-GESIC
IBU-SLO
ACHES-N-PAIN
BRUFEN RET
MIDOL
CHILDREN'S ELIXSURE
SECLODIN
CO-OP
ARTHROFEN 600
CUPROFEN FOR CHILD
IBUPROHM
NUROFEN CHILD
IBUPROFEN
PHOR PAIN
ISISFEN
IBUMOUSSE
RD 13621
MANORFEN
NUPRIN
MANDAFEN
RUFEN
CODAFEN CONTINUS
MOTRIN MIGRAINE PAIN
ARTHROFEN 200
NUROFEN FOR CHILD
IBULAR
JUNIFEN
ADVIL®
P-ISOBUTYL-2-PHENYLPROPIONATE
(±)-2-(P-ISOBUTYLPHENYL)PROPIONIC ACID
(+-)-2-(P-ISOBUTYLPHENYL)PROPIONIC ACID
ALPHA-(4-ISOBUTYLPHENYL)PROPIONATE
P-ISOBUTYLHYDRATROPIC ACID
ALPHA-(4-ISOBUTYLPHENYL)PROPIONIC ACID
IBUPROPHEN
DURALBUPROFEN
ALPHA-P-ISOBUTYLPHENYLPROPIONATE
MOTRIN®
(+-)-IBUPROFEN
NUROFEN®
P-ISOBUTYLHYDRATROPATE
Α-(4-ISOBUTYLPHENYL)PROPIONIC ACID
Α-(P-ISOBUTYLPHENYL)PROPIONIC ACID
ALPHA-P-ISOBUTYLPHENYLPROPIONIC ACID
2-(4-ISOBUTYLPHENYL)PROPANOIC ACID
BRUFEN®
(±)-IBUPROFEN
ALPHA-(P-ISOBUTYLPHENYL)PROPIONIC ACID
P-ISOBUTYL-2-PHENYLPROPIONIC ACID
(+-)-ALPHA-METHYL-4-(2-METHYLPROPYL)BENZENEACETIC ACID
(4-ISOBUTYLPHENYL)-Α-METHYLACETIC ACID
(+-)-P-ISOBUTYLHYDRATROPIC ACID
(±)-Α-METHYL-4-(2-METHYLPROPYL)BENZENEACETIC ACID
(4-ISOBUTYLPHENYL)-ALPHA-METHYLACETIC ACID
4-ISOBUTYLHYDRATROPIC ACID
(RS)-IBUPROFEN
(±)-P-ISOBUTYLHYDRATROPIC ACID
rxcui:5640
chemidplus:15687-27-1
drugbank:01050
chembl:CHEMBL521
pubchem.compound:3672

Drug Info:

Drug Class	anti-inflammatory agents, non-steroidal
Year of Approval	1984
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	NSAID

(6 More Sources)

Publications:

Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics
Grosser T, 2009, Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy., J Investig Med
Lee YS et al., 2006, Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs., Clin Pharmacol Ther
Ouellet et al., 2004, Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms., Biochem. J.
Gallego-Sandín et al., 2004, Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa: correlation with endoscopic lesions and adverse reactions., Dig. Dis. Sci.
Sánchez-Fidalgo et al., 2004, Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor., Eur. J. Pharmacol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Chavez et al., 2003, Valdecoxib: a review., Clin Ther
Murphey et al., 2004, Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer., Anal. Biochem.
Vitale P et al., 2013, Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors., J Med Chem
Gupta et al., 2004, Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors., Bioorg. Med. Chem. Lett.
Yu et al., 2013, Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro., Biopharm Drug Dispos
Martić et al., 2004, Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors., Eur J Med Chem
Patrignani, 2003, Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease., Thromb. Res.
Hillarp, 2004, [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism]., Lakartidningen
Buchanan et al., 2007, Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer., Cancer Res.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Vrtic et al., 2003, Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug., Br J Clin Pharmacol
Abran et al., 1997, Characterization and regulation of prostaglandin E2 receptor and receptor-coupled functions in the choroidal vasculature of the pig during development., Circ. Res.
Chemtob et al., 1996, Regulation of cerebrovascular prostaglandin E2 (PGE2) and PGF2 alpha receptors and their functions during development., Semin. Perinatol.
Quidville et al., 2006, 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line., Prostaglandins Other Lipid Mediat.
Jakubíková et al., 2001, Non-steroidal anti-inflammatory agent ibuprofen-induced apoptosis, cell necrosis and cell cycle alterations in human leukemic cells in vitro., Neoplasma
Hockertz et al., 1996, Treatment of an acute bacterial infection with a combination of acetylsalicylic acid/ibuprofen and interferon gamma., Arzneimittelforschung
Palayoor et al., 2004, Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function., Clin. Cancer Res.
Zajic SC et al., 2019, Individuals with CYP2C8 and CYP2C9 reduced metabolism haplotypes self-adjusted ibuprofen dose in the Coriell Personalized Medicine Collaborative., Pharmacogenet Genomics
Ochoa D et al., 2015, Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers., Pharmacogenomics
García-Martín E et al., 2004, Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms., Clin Pharmacol Ther
Karaźniewicz-Łada M et al., 2009, Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes., Xenobiotica
López-Rodríguez R et al., 2008, Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers., Pharmacol Res
Blanco G et al., 2008, Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding., Pharmacogenet Genomics
Brueggemeier et al., 2005, Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer., J. Steroid Biochem. Mol. Biol.
Tsutsumi et al., 2004, Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis., Cell Death Differ.
Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med

IBUPROFEN AMACR

Interaction Score: 3.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
IBUPROFEN UGT2B17

Interaction Score: 3.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
IBUPROFEN UGT2B4

Interaction Score: 3.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
IBUPROFEN PTGER4

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9118476

Sources:
NCI
IBUPROFEN PTGER1

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9118476 8870119

Sources:
NCI
IBUPROFEN CYP2C8

Interaction Score: 0.62

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30562214 26122864 25502615 15289789 19480553 18694831 18216720

Sources:
PharmGKB
IBUPROFEN PTGS1

Interaction Score: 0.44

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name HZT-501, ibuprofen + famotidine,Duexa

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
23651359 14741265 23536207 14987823 11752352 12852704 14592549 15575422 25502615

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB
IBUPROFEN CXCR1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
IBUPROFEN PTGS2

Interaction Score: 0.33

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name HZT-501, ibuprofen + famotidine,Duexa

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
25502615 19602986 16678543 14510637 15481334 15556152 11752352 12852704 15494133

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
IBUPROFEN UGT1A3

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
IBUPROFEN VHL

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15217953

Sources:
NCI
IBUPROFEN IFNG

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8931897

Sources:
NCI
IBUPROFEN UGT1A9

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
IBUPROFEN APC

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
17909047

Sources:
JAX-CKB
IBUPROFEN UGT2B7

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
IBUPROFEN FAAH

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
IBUPROFEN NOS2

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
IBUPROFEN NOS3

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
IBUPROFEN CXCR2

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
IBUPROFEN DDIT3

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15131590

Sources:
NCI
IBUPROFEN CYP19A1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15964185

Sources:
NCI
IBUPROFEN NOS1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615

Sources:
PharmGKB
IBUPROFEN CXCL8

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
IBUPROFEN PIK3CA

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30683736

Sources:
CIViC
IBUPROFEN TARDBP

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
IBUPROFEN CYP2C19

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615 22931300

Sources:
DTC PharmGKB
IBUPROFEN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11583291

Sources:
NCI
IBUPROFEN HPGD

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16997128

Sources:
NCI
IBUPROFEN CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 12580991

Sources:
DTC NCI
IBUPROFEN CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
IBUPROFEN CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25502615 22931300

Sources:
DTC PharmGKB
IBUPROFEN CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC

TEND: IBUPROFEN
- Version: 01-August-2011
Alternate Names:

Drug Info:

Year of Approval 1984

Drug Class anti-inflammatory agents, non-steroidal

Publications:
TdgClinicalTrial: IBUPROFEN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications NSAID

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: IBUPROFEN

Version: 14-September-2017

Alternate Names:

C561 NCI drug code

Drug Info:

Publications:

Chemtob et al., 1996, Regulation of cerebrovascular prostaglandin E2 (PGE2) and PGF2 alpha receptors and their functions during development., Semin. Perinatol.

Abran et al., 1997, Characterization and regulation of prostaglandin E2 receptor and receptor-coupled functions in the choroidal vasculature of the pig during development., Circ. Res.

Jakubíková et al., 2001, Non-steroidal anti-inflammatory agent ibuprofen-induced apoptosis, cell necrosis and cell cycle alterations in human leukemic cells in vitro., Neoplasma

DTC: IBUPROFEN

Version: 02-September-2020

Alternate Names:

CHEMBL521 ChEMBL Drug ID

Drug Info:

Publications:

Vitale P et al., 2013, Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors., J Med Chem

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

JAX-CKB: Ibuprofen
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Buchanan et al., 2007, Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer., Cancer Res.

PharmGKB: ibuprofen

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Mazaleuskaya LL et al., 2015, PharmGKB summary: ibuprofen pathways., Pharmacogenet Genomics

Lee YS et al., 2006, Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs., Clin Pharmacol Ther

Grosser T, 2009, Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy., J Investig Med

CIViC: IBUPROFEN
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med
TTD: Ibuprofen
- Version: 2020.06.01
Alternate Names:

D0R1QE TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL521
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL521
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	HZT-501, ibuprofen + famotidine,Duexa
Novel drug target	Established target
Mechanism of Interaction	Cyclooxygenase inhibitor

Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft
Response Type	sensitive

IBUPROFEN Drug Record

IBUPROFEN chembl:CHEMBL521 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25502615

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25502615

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25502615

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9118476

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9118476 8870119

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30562214 26122864 25502615 15289789 19480553 18694831 18216720

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name HZT-501, ibuprofen + famotidine,Duexa Novel drug target Established target Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs: 23651359 14741265 23536207 14987823 11752352 12852704 14592549 15575422 25502615

Sources: DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name HZT-501, ibuprofen + famotidine,Duexa Novel drug target Established target Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs: 25502615 19602986 16678543 14510637 15481334 15556152 11752352 12852704 15494133

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25502615

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15217953

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8931897

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25502615

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell line xenograft Response Type sensitive

PMIDs: 17909047

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25502615

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25502615

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25502615

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25502615

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9118476

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9118476 8870119

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
30562214 26122864 25502615 15289789 19480553 18694831 18216720

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name HZT-501, ibuprofen + famotidine,Duexa

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
23651359 14741265 23536207 14987823 11752352 12852704 14592549 15575422 25502615

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name HZT-501, ibuprofen + famotidine,Duexa

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
25502615 19602986 16678543 14510637 15481334 15556152 11752352 12852704 15494133

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15217953

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8931897

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
17909047

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
15131590

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15964185

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25502615

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
30683736

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25502615 22931300